Regenerative Medical Technology (RMTG) Current Deferred Revenue (2021 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Current Deferred Revenue of $504892.0 for Q1 2026, up 1309.68% year-over-year from $35816.0 in Q1 2025, and up 43.76% quarter-over-quarter from $351193.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Current Deferred Revenue (2021 - 2026) Analysis & Trends
Regenerative Medical Technology's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $504892.0 for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 1309.68% year-over-year to $504892.0; the TTM figure through Mar 2026 stood at $504892.0 (up 1309.68% YoY), while the FY2025 annual figure was $351193.0, up 530.69% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $504892.0, up from $351193.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $504892.0 in Q1 2026, with the low at $500.0 in Q2 2023.
- The 5-year median for Current Deferred Revenue is $67767.0 (2024), against an average of $131717.8.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 80.86% in 2023, then jumped 74472.0% in 2024.
- Regenerative Medical Technology's Current Deferred Revenue stood at $10450.0 in 2022, then tumbled by 80.86% to $2000.0 in 2023, then surged by 2684.2% to $55684.0 in 2024, then soared by 530.69% to $351193.0 in 2025, then jumped by 43.76% to $504892.0 in 2026.
- Business Quant data shows RMTG's Current Deferred Revenue at $504892.0 in Q1 2026, $351193.0 in Q4 2025, and $172146.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 504,892.00 |
| Dec 31, 2025 | 351,193.00 |
| Sep 30, 2025 | 172,146.00 |
| Jun 30, 2025 | 121,770.00 |
| Mar 31, 2025 | 35,816.00 |
| Dec 31, 2024 | 55,684.00 |
| Sep 30, 2024 | 79,850.00 |
| Jun 30, 2024 | 372,860.00 |
| Mar 31, 2024 | 114,880.00 |
| Dec 31, 2023 | 2,000.00 |
| Sep 30, 2023 | 1,500.00 |
| Jun 30, 2023 | 500.00 |
| Mar 31, 2023 | 20,508.00 |
| Dec 31, 2022 | 10,450.00 |
| Dec 31, 2021 | 18,215.00 |